Humana Inc.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It's Moving
Humana trims outlook amid Medicare woes but fuels pharmacy growth hopes
Humana recently cut its full-year earnings outlook due to persistent Medicare Advantage pressures, yet reaffirmed its 2025 guidance in December meetings, signaling management confidence. Investors are eyeing potential upside from a rumored Mark Cuban pharmacy partnership and CenterWell expansion as counters to sector headwinds.
- Earnings outlook trimmed as Medicare reimbursement challenges persist, pressuring short-term profitability.[1]
- Reaffirmed 2025 earnings guidance in recent meetings, underscoring steady long-term financial trajectory.[2]
- Pharmacy division growth and possible Mark Cuban partnership spark optimism, offsetting recent share weakness and positioning HUM as undervalued vs. analyst targets.[1][3]
Humana trims outlook amid Medicare woes but fuels pharmacy growth hopes
Humana recently cut its full-year earnings outlook due to persistent Medicare Advantage pressures, yet reaffirmed its 2025 guidance in December meetings, signaling management confidence. Investors are eyeing potential upside from a rumored Mark Cuban pharmacy partnership and CenterWell expansion as counters to sector headwinds.
- Earnings outlook trimmed as Medicare reimbursement challenges persist, pressuring short-term profitability.[1]
- Reaffirmed 2025 earnings guidance in recent meetings, underscoring steady long-term financial trajectory.[2]
- Pharmacy division growth and possible Mark Cuban partnership spark optimism, offsetting recent share weakness and positioning HUM as undervalued vs. analyst targets.[1][3]
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Humana's stock with a target price of $286.26, indicating potential for growth.
Financial Health
Humana Inc. shows solid revenue and cash flow, indicating good financial performance and stability.
Dividend
Humana's dividend yield of 1.32% is relatively low, making it less appealing for dividend-focused investors. If you invested $1000 you would be paid $13.54 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring HUM
Government Shutdown Impact: Defensive Stocks Explained
A U.S. government shutdown has been triggered by a congressional budget impasse, creating economic uncertainty. This theme focuses on companies in defensive sectors that may prove resilient to the resulting market volatility and disruptions in federal spending.
Published: October 2, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketDefensive Plays Amid Fed Turmoil
The removal of a Federal Reserve governor has created political and financial uncertainty, shaking confidence in the central bank's stability. This environment could create opportunities for investments in defensive sectors and assets that are traditionally seen as safe havens during periods of market volatility.
Published: August 26, 2025
Explore BasketFollowing Buffett's Healthcare Bet
Warren Buffett's Berkshire Hathaway is making a major $2.1 billion bet on UnitedHealth, signaling a strategic shift toward the healthcare sector. This theme focuses on other health insurers and healthcare providers that could benefit from this renewed investor confidence.
Published: August 15, 2025
Explore BasketHealthcare In The Crosshairs: Insurers Under Scrutiny
The Department of Justice is investigating UnitedHealth Group's Medicare billing, creating uncertainty for the nation's largest insurer. This situation presents a potential opportunity for rival health insurers to gain market share and for compliance-focused companies that help the industry navigate complex regulations.
Published: July 25, 2025
Explore BasketHealthcare Billing Integrity
This group of stocks includes companies positioned to benefit from increased focus on healthcare billing compliance. Carefully selected by professional analysts, these stocks represent both healthcare tech providers offering compliance solutions and competing insurers who may gain market share amid regulatory scrutiny.
Published: July 11, 2025
Explore BasketMedicaid Politics
Discover companies whose fortunes are closely tied to government healthcare funding decisions. These carefully selected stocks represent businesses with significant exposure to Medicaid, now facing heightened legislative uncertainty after Senator Tillis's retirement.
Published: June 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Chemed Corp.
Provides hospice and palliative care services to patients facing life-limiting illness
Alignment Healthcare, Inc.
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale Senior Living Inc.
A leading owner and operator of senior living communities in the United States.
